Vaxinano is engaged in the development of prophylactic and therapeutic vaccines for infectious diseases, for human and animal health markets. The company is using nanoparticles made of starch and lipids (nanovectors) to develop vaccines. The company's experimental vaccines target toxoplasmosis and tuberculosis and developing anti-bacterial, antiviral and antiparasitic vaccines. The company operates in the Infectious Diseases sector with additional focus on Infectious Diseases and Immunotherapy. Its business model centers on Vaccine. Founded in 2016, headquartered in Lille, France. The company has raised $6.5M at the Series A stage. Backed by investors including TCD Capital, Nord France Amorquage, WiSEED, Bpifrance, Captechsantenutrition and others.
← All startups
Vaxinano
Series AVaxinano is engaged in the development of prophylactic and therapeutic vaccines for infectious diseases, for human and animal health markets. The company is using nanoparticles made of starch and lipids (nanovectors) to develop vaccines. The company's experimental vaccines target toxoplasmosis and tuberculosis and developing anti-bacterial, antiviral and antiparasitic vaccines. The company operates in the Infectious…
About
Business model
Nanotechnology > Nanoenabled Products > Life Science > Drug Delivery > Vaccine,
Infectious Diseases > Drugs > Diversified,
Drug Delivery > Nanoparticle Based
Team background
College Wise > HEC Paris
Institutional investors
TCD CapitalNord France AmorquageWiSEEDBpifranceCaptechsantenutritionANR
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ Explore Life Sciences investors — funds that write checks in this sector.